p53-independent functions of MDM2.

The tumor suppressor p53 is inactivated by overexpression of MDM2 in about 10% of human tumors. However, p53 is inactivated by other mechanisms in the majority of tumors, raising the possibility that MDM2 may be irrelevant to transformation in most cases. However, MDM2 has been reported to have p53-independent functions, in cell cycle control, differentiation, cell fate determination, DNA repair, basal transcription, and other processes. Furthermore, MDM2 appears to contribute to the transformed phenotype in the absence of wild-type p53. Nevertheless, the number of studies is still limited, and the evidence in some cases does not unequivocally show that the functions are p53 independent. We will discuss the circuits of regulation involving MDM2 that do not directly concern p53. Hopefully, future work will consolidate our understanding of the p53-independent pathological functions of MDM2 and will lead to useful therapeutic interventions that target the majority of tumors.

[1]  S. Deb,et al.  N-terminal 130 amino acids of MDM2 are sufficient to inhibit p53-mediated transcriptional activation. , 1995, Oncogene.

[2]  J. Piette,et al.  Mdm2: keeping p53 under control , 1997, Oncogene.

[3]  A. Jochemsen,et al.  MDMX: a novel p53‐binding protein with some functional properties of MDM2. , 1996, The EMBO journal.

[4]  J. Massagué,et al.  Different Sensitivity of the Transforming Growth Factor-β Cell Cycle Arrest Pathway to c-Myc and MDM-2* , 2000, The Journal of Biological Chemistry.

[5]  F. McKeon,et al.  Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. , 1999, The Journal of investigative dermatology.

[6]  S. Burley.  The TATA box binding protein. , 1996, Current opinion in structural biology.

[7]  J. Reed,et al.  p53-regulated apoptosis is differentiation dependent in ultraviolet B-irradiated mouse keratinocytes. , 1998, The American journal of pathology.

[8]  D. Haines.  The mdm2 proto-oncogene. , 1997, Leukemia & lymphoma.

[9]  E. White,et al.  Suppression of the p300-dependent mdm2 negative-feedback loop induces the p53 apoptotic function. , 1998, Genes & development.

[10]  Yue Xiong,et al.  ARF Promotes MDM2 Degradation and Stabilizes p53: ARF-INK4a Locus Deletion Impairs Both the Rb and p53 Tumor Suppression Pathways , 1998, Cell.

[11]  J. Piette,et al.  MDM-2 protein is expressed in different layers of normal human skin , 1997, Oncogene.

[12]  Xin Lu,et al.  RB regulates the stability and the apoptotic function of p53 via MDM2. , 1999, Molecular cell.

[13]  S. Grossman,et al.  Physical and Functional Interactions between PML and MDM2* , 2003, Journal of Biological Chemistry.

[14]  W. Kaelin,et al.  Transcriptional control by E2F. , 1995, Seminars in cancer biology.

[15]  S. Guerrera,et al.  MDM2 interacts with the C-terminus of the catalytic subunit of DNA polymerase epsilon. , 2000, Nucleic acids research.

[16]  B. Wasylyk,et al.  MDM2 overexpression generates a skin phenotype in both wild type and p53 null mice , 1999, Oncogene.

[17]  A. Levine,et al.  Regulation of the p53 protein by the MDM2 oncoprotein--thirty-eighth G.H.A. Clowes Memorial Award Lecture. , 1999, Cancer research.

[18]  R. Ramirez-Solis,et al.  mdmx is a negative regulator of p53 activity in vivo. , 2002, Cancer research.

[19]  Hui Wang,et al.  MDM2 oncogene as a novel target for human cancer therapy. , 2000, Current pharmaceutical design.

[20]  J. Blaydes,et al.  p53-independent activation of the hdm2-P2 promoter through multiple transcription factor response elements results in elevated hdm2 expression in estrogen receptor alpha-positive breast cancer cells. , 2003, Cancer research.

[21]  D. Livingston,et al.  p300/MDM2 complexes participate in MDM2-mediated p53 degradation. , 1998, Molecular cell.

[22]  G. Lozano,et al.  Targeted expression of MDM2 uncouples S phase from mitosis and inhibits mammary gland development independent of p53. , 1997, Genes & development.

[23]  T. Léveillard,et al.  MDM2 expression during mouse embryogenesis and the requirement of p53 , 1998, Mechanisms of Development.

[24]  T. Kohout,et al.  Regulation of Receptor Fate by Ubiquitination of Activated β2-Adrenergic Receptor and β-Arrestin , 2001, Science.

[25]  A. Levine,et al.  Molecular abnormalities of mdm2 and p53 genes in adult soft tissue sarcomas. , 1994, Cancer research.

[26]  Ken Chen,et al.  The Ink4a Tumor Suppressor Gene Product, p19Arf, Interacts with MDM2 and Neutralizes MDM2's Inhibition of p53 , 1998, Cell.

[27]  C. Azzoli,et al.  p53-mediated transcriptional activity increases in differentiating epidermal keratinocytes in association with decreased p53 protein. , 1995, Oncogene.

[28]  T. Mak,et al.  p53 accumulation, defective cell proliferation, and early embryonic lethality in mice lacking tsg101. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[29]  H. Vogel,et al.  p63 is a p53 homologue required for limb and epidermal morphogenesis , 1999, Nature.

[30]  Christopher P. Crum,et al.  p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development , 1999, Nature.

[31]  D. Lane,et al.  High levels of p53 protein in UV-irradiated normal human skin. , 1993, Oncogene.

[32]  M. Kubbutat,et al.  Identification of a cryptic nucleolar-localization signal in MDM2 , 2000, Nature Cell Biology.

[33]  B. Wasylyk,et al.  MDM2 induces hyperplasia and premalignant lesions when expressed in the basal layer of the epidermis , 2000, The EMBO journal.

[34]  N. L. La Thangue,et al.  Apoptotic and Growth-Promoting Activity of E2F Modulated by MDM2 , 2000, Molecular and Cellular Biology.

[35]  T. Ishikawa,et al.  p53-Dependent Regulation of Nucleotide Excision Repair in Murine Epidermis in vivo , 1998, Journal of cutaneous medicine and surgery.

[36]  L. Donehower,et al.  Overexpression of Mdm2 in mice reveals a p53-independent role for Mdm2 in tumorigenesis. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[37]  Charles A. Thomas,et al.  The human oncoprotein MDM2 arrests the cell cycle: elimination of its cell‐cycle‐inhibitory function induces tumorigenesis , 1998, The EMBO journal.

[38]  Tony Kouzarides,et al.  Stimulation of E2F1/DP1 transcriptional activity by MDM2 oncoprotein , 1995, Nature.

[39]  S. Deb.  Cell cycle regulatory functions of the human oncoprotein MDM2. , 2003, Molecular cancer research : MCR.

[40]  S. Berberich,et al.  Mdm2 inhibition of p53 induces E2F1 transactivation via p21 , 2002, Oncogene.

[41]  F. McCormick,et al.  Opposing Effects of Ras on p53 Transcriptional Activation of mdm2 and Induction of p19ARF , 2000, Cell.

[42]  Hui Wang,et al.  Antisense anti-MDM2 oligonucleotides as a novel therapeutic approach to human breast cancer: in vitro and in vivo activities and mechanisms. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[43]  J. Manley,et al.  Interaction between a transcriptional activator and transcription factor IIB in vivo , 1993, Nature.

[44]  C. Degnin,et al.  Regulation of MyoD Activity and Muscle Cell Differentiation by MDM2, pRb, and Sp1* , 2003, Journal of Biological Chemistry.

[45]  B. Wasylyk,et al.  Ligand-dependent interaction of the glucocorticoid receptor with p53 enhances their degradation by Hdm2. , 2001, Genes & development.

[46]  Hua Lu,et al.  The Acetylase Activity of p300 Is Dispensable for MDM2 Stabilization* , 2003, The Journal of Biological Chemistry.

[47]  T. Léveillard,et al.  The MDM2 C-terminal Region Binds to TAFII250 and Is Required for MDM2 Regulation of the Cyclin A Promoter* , 1997, The Journal of Biological Chemistry.

[48]  A. Levine,et al.  Conservation of structural domains and biochemical activities of the MDM2 protein from Xenopus laevis , 1997, Oncogene.

[49]  W. Sellers,et al.  Interaction between the retinoblastoma protein and the oncoprotein MDM2 , 1995, Nature.

[50]  H. Findley,et al.  MDM2 induces NF-kappaB/p65 expression transcriptionally through Sp1-binding sites: a novel, p53-independent role of MDM2 in doxorubicin resistance in acute lymphoblastic leukemia. , 2002, Blood.

[51]  C. Blattner,et al.  Transcription Factor E2F-1 Is Upregulated in Response to DNA Damage in a Manner Analogous to That of p53 , 1999, Molecular and Cellular Biology.

[52]  Yolande F M Ramos,et al.  Isolation and identification of the human homolog of a new p53-binding protein, Mdmx. , 1997, Genomics.

[53]  V. Reinke,et al.  Overproduction of MDM2 in vivo disrupts S phase independent of E2F1. , 1999, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[54]  L. Mayo,et al.  A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of Mdm2 from the cytoplasm to the nucleus , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[55]  L. Chin,et al.  The INK4a/ARF tumor suppressor: one gene--two products--two pathways. , 1998, Trends in biochemical sciences.

[56]  V. Rotter,et al.  Involvement of p53 in cell differentiation and development. , 1997, Biochimica et biophysica acta.

[57]  K. Helin,et al.  Mdm4 (Mdmx) Regulates p53-Induced Growth Arrest and Neuronal Cell Death during Early Embryonic Mouse Development , 2002, Molecular and Cellular Biology.

[58]  G. Lozano,et al.  Loss of p19ARF enhances the defects of Mdm2 overexpression in the mammary gland , 2002, Oncogene.

[59]  T. Unger,et al.  The Mdm2 Oncoprotein Interacts with the Cell Fate Regulator Numb , 1998, Molecular and Cellular Biology.

[60]  D. Haines,et al.  A Novel Cellular Protein (MTBP) Binds to MDM2 and Induces a G1 Arrest That Is Suppressed by MDM2* , 2000, The Journal of Biological Chemistry.

[61]  A. Levine,et al.  P19(ARF) stabilizes p53 by blocking nucleo-cytoplasmic shuttling of Mdm2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Yong Liao,et al.  HER-2/neu induces p53 ubiquitination via Akt-mediated MDM2 phosphorylation , 2001, Nature Cell Biology.

[63]  Michael R. Green,et al.  Interaction between an acidic activator and transcription factor TFIIB is required for transcriptional activation , 1993, Nature.

[64]  B. Wasylyk,et al.  Defect in the p53-Mdm2 Autoregulatory Loop Resulting from Inactivation of TAFII250 in Cell Cycle Mutant tsBN462 Cells , 2000, Molecular and Cellular Biology.

[65]  J. Nevins,et al.  E2F1-specific induction of apoptosis and p53 accumulation, which is blocked by Mdm2. , 1998, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[66]  A. Levine,et al.  The MDM2 Oncoprotein Binds Specifically to RNA through its RING Finger Domain , 1996, Molecular medicine.

[67]  H. Taubert,et al.  Alternative and aberrant splicing of MDM2 mRNA in human cancer. , 2002, Cancer cell.

[68]  A. Levine,et al.  The ribosomal L5 protein is associated with mdm-2 and mdm-2-p53 complexes , 1994, Molecular and cellular biology.

[69]  S. Tapscott,et al.  Amplification of MDM2 inhibits MyoD-mediated myogenesis , 1996, Molecular and cellular biology.

[70]  G. Strous,et al.  β-Arrestin and Mdm2, Unsuspected Partners in Signaling from the Cell Surface , 2001, Science's STKE.

[71]  Ying Li,et al.  Stimulation of human DNA polymerase ϵ by MDM2 , 2003 .

[72]  C. Cordon-Cardo,et al.  Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[73]  Hsiao-Huei Wu,et al.  MDM2--master regulator of the p53 tumor suppressor protein. , 2000, Gene.

[74]  T. Mak,et al.  A TSG101/MDM2 regulatory loop modulates MDM2 degradation and MDM2/p53 feedback control. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[75]  L. Mayo,et al.  The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. , 2002, Trends in biochemical sciences.

[76]  P. Lambert,et al.  Different responses of epidermal and hair follicular cells to radiation correlate with distinct patterns of p53 and p21 induction. , 1999, The American journal of pathology.

[77]  G. Hannon,et al.  p53-Independent Role of MDM2 in TGF-β1 Resistance , 1998 .

[78]  R. Honda,et al.  Mammalian Numb is a target protein of Mdm2, ubiquitin ligase. , 2003, Biochemical and biophysical research communications.

[79]  M. Oren,et al.  Mdm2: The Ups and Downs , 1999, Molecular medicine.

[80]  B. Wasylyk,et al.  MDM2 transformation in the absence of p53 and abrogation of the p107 G1 cell-cycle arrest. , 1995, Oncogene.

[81]  E. Shaulian,et al.  Induction of Mdm2 and enhancement of cell survival by bFGF , 1997, Oncogene.

[82]  C. Prives.  Signaling to p53 Breaking the MDM2–p53 Circuit , 1998, Cell.

[83]  F. Zindy,et al.  Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[84]  T. Cooper,et al.  Pre-mRNA splicing and human disease. , 2003, Genes & development.

[85]  Karen H. Vousden,et al.  p14ARF links the tumour suppressors RB and p53 , 1998, Nature.